In the phase III RCT studies, the majority of participants had primary CDI episodes (73%) and were hospitalized at the time of recruitment (68%) [18]. Cornely OA, Miller MA, Louie TJ, Crook DW, Gorbach SL. Amcor and Bemis combination Unanimously recommended by the Boards of Directors of both companies Amcor shareholders will receive one New Amcor CDI or share for each existing share held New Amcor to be NYSE and ASX listed Amcor and Bemis shareholders expected to own approximately 71% and 29% respectively The Committees granting of an Incentive Award to a Participant at any time shall neither require the Committee to grant an Incentive Award to such Participant or any other Participant or other Person at any time nor preclude the Committee from making subsequent grants to such Participant or any other Participant or other Person. Investors can use this forecasting interface to forecast AMCOR PLC historical stock prices and determine the direction of AMCOR PLC CDI's future trends based on various well-known forecasting models. Gerding DN, Kelly CP, Rahav G, et al. Initial clinical responses are similar for both agents, whereas CDI recurrences are fewer following fidaxomicin. Two alerts document transmission of pathogenicEscherichia colifrom donor to FMT recipients, some of whom became ill and some of whom died [35]. In particular, studies with more appropriate controls for extended-pulsed fidaxomicin should help clarify the role of this dosing strategy for patients with recurrent CDI both in terms of efficacy and quality of life. The comparison in this study, however, was a standard course of vancomycin and the sustained response achieved was similar to that achieved in the phase III trials comparing a standard course of fidaxomicin with vancomycin [35]. It should be noted that vancomycin also predictably results in a successful initial clinical cure, even for patients with recurrent CDI, and vancomycin in an extended, tapered, and pulsed regimen has been used successfully in managing patients with multiple CDI recurrences [32]. Vancomycin remains an acceptable alternative. (p) Exchange Act means the Securities Exchange Act of 1934, as amended. No provision of this Section14 shall be given effect to the extent that such provision would cause any tax to become due under Section409A of the Code with regard to Incentive Awards subject to Section409A of the Code. Notwithstanding the foregoing and subject to the terms of an Award Agreement, in the event of a Change in Control, each outstanding Incentive Award shall be treated as the Committee determines, including, without limitation that (x)Incentive Awards may be continued, assumed, or substantially equivalent Incentive Awards may be substituted, by the acquiring or succeeding corporation (or an affiliate thereof) with appropriate adjustments as to. This guideline is intended for use by healthcare professionals who care for adults with CDI, including specialists in infectious diseases, gastroenterologists, hospitalists, pharmacists . Amcor shareholder might subsequently make from their replacement New Amcor share or CDI would be disregarded, except because of a roll-over (paragraph 124-795(2)(a)). PDF Corporate - assets.ctfassets.net In patients with a history of CHF, the FDA warns that bezlotoxumab should be reserved for use when the benefit outweighs the risk. C. P. K. serves as an advisor for Matrivax, Vedanta, Merck, Cour, Acurx Pharmaceuticals, Finch, Microbiota, and Milky Way Life Science; has served as an advisor for Artugen, Glutenostix, Innovate, and Sanofi; receives honoraria from Merck for serving as a symposium speaker; has received honoraria from Biocodex for serving as a symposium speaker; has held stock in Glutenostix; receives research funding from the NIH and the National Institute of Allergy and Infectious Diseases; has received research funding from Instit Merieux, Merck, and Allergan; currently serves as the President of the Society for the Study of Celiac Disease and as the Secretary for the Foundation for Celiac Disease Outcome Measures; and his organization, Beth Israel Deaconess Medical Center, has received organizational benefits from the Sydney Frank Foundation and Milky Way Life Sciences. Despite these considerations, the use of bezlotoxumab is considered likely acceptable to patients and their providers and feasible to implement. (i) Committee means the Compensation Committee of the Board of Directors or such other committee as the Board of Directors shall appoint from time to time to administer the Plan and to otherwise exercise and perform the authority and functions assigned to the Committee under the terms of the Plan. Rights Under the Plan, No Person shall have any rights as a shareholder with respect to any Shares covered by or relating to any Incentive Award until the date of the issuance of such Shares on the books and records of Amcor. ZURICH, Feb. 7, 2023 /PRNewswire/ -- Amcor CEO Ron Delia said: "Amcor . Sirbu BD, Soriano MM, Manzo C, Lum J, Gerding DN, Johnson S. Vancomycin taper and pulse regimen with careful follow-up for patients with recurrent Clostridium difficile infection. Patient-important outcomes were all reported in the study published by Wilcox et al [18], except for CDI-associated hospital readmission, which was only reported in a subgroup analysis of patients hospitalized at the time of randomization [18,19] (seeFigure 3). This assessment of disclosed relationships for possible COIs was based on the relative weight of the financial relationship (ie, monetary amount) and the relevance of the relationship (ie, the degree to which an independent observer might reasonably interpret an association as related to the topic or recommendation of consideration). Mr Delia said this week that Amcor shareholders have the choice of taking up the New York-listed shares or owning CDIs listed on the ASX, and disagreed with suggestions Australian investors might be left with a second-best option. Investors & Shareholders FAQ | Amcor (e) No Other Rights. Additional, well-designed, independent, cost-effectiveness studies for patients with CDI are needed to improve the strength of this recommendation given that cost is a substantial barrier to fidaxomicin use. Amcor Limited (ASX: AMC) is a global packaging company. In settings where logistics is not an issue, patients with a primary CDI episode and other risk factors for CDI recurrence (such as age 65 years, immunocompromised host [per history or use of immunosuppressive therapy], and severe CDI on presentation) may particularly benefit from receiving bezlotoxumab. Open Forum Infect Dis 2020; 7:ofaa097. This includes if you've received dividend's from this particular share portfolio. What does Amcor mean? Both of these agents have increased clinical efficacy and other advantages over older agents, but implementation may be challenging because of initial monetary cost and logistics. Furthermore, the studies demonstrating equivalent efficacy for fidaxomicin and vancomycin in initial clinical response to therapy for CDI generally excluded patients with fulminant disease. As per the GRADE approach, all outcomes are not considered equally important in the decision-making process. In the event of any change in the number of Shares of Amcor outstanding by reason of any other event or transaction, the Committee shall, to the extent deemed appropriate by the Committee, make such adjustments to the type or number of Shares with respect to which Incentive Awards may be granted and/or to the number of Shares subject to Incentive Awards. Risk of CDI recurrence also increased with the number of risk factors; patients with 1 risk factor experienced a 31.3% likelihood of CDI recurrence compared with a 46.1% likelihood in patients with 3 or more risk factors. Our update of the literature identified 2 more recently published RCTs [16,17] addressing similar clinical questions (seeFigure 2). The reader of these guidelines should be mindful of this when the list of disclosures is reviewed. It is important to realize that guidelines cannot always account for individual variation among patients. To assess who might benefit the most from receiving bezlotoxumab in addition to SOC, we completed an additional post hoc subgroup analysis using data supplied by the sponsor of the MODIFY trials to estimate the effect of using bezlotoxumab on CDI recurrence after initial clinical cure at 12 weeks in patients with recurrent CDI. Singapore Telecom had CDIs trading on the ASX for 14 years following its 2001 takeover of Optus, but killed them off in June 2015 because the liquidity had dropped to low levels. Plastic packaging manufacturer Amcor is the latest Australian company that will surrender its primary Australian listing on the back of a cross-border transaction in favour of a locally listed CDI . Investors fret Amcor CDI is first step to eventual exit When treating patients for a second or subsequent recurrence, the guideline recommends pulse-tapered vancomycin or vancomycin for 10 days followed by rifaximin or fidaxomicin. However, its cost may be prohibitive without adequate insurance coverage. Approximately every 2 years, and more frequently if needed, IDSA and SHEA will determine the need for revisions to the guideline by an examination of the current literature and the likelihood that any new data will have an impact on the recommendations. As used in the Plan or in any instrument governing the terms of any Incentive Award, the following definitions apply to the terms indicated below: (a) Affiliate means, with respect to a specified Person, a Person that directly, or indirectly through one or more intermediaries, controls or is controlled by, or is under common control with, the specified Person. Identifying patients with primary CDI who might benefit from bezlotoxumab and establishing a referral to an infusion center is complicated by the fact that they are typically not seen by infectious diseases or gastroenterology specialists but are initially managed by primary care or other physicians often without experience managing CDI. The grant of a Cash-Based Award shall not require a segregation of any of the Companys assets for satisfaction of the Companys payment obligation thereunder. More well-designed RCTs for patients with recurrent CDI, particularly multiply recurrent CDIs, are needed to improve the strength of recommendations. Rubio-Terrs C, Aguado JM, Almirante B, et al.